First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

by Cyrus Huneycutt | Nov 14, 2023 | 0 comments

Submit a Comment Cancel reply

You must be logged in to post a comment.